King Luther Capital Management Corp Has $12.92 Million Holdings in Charles River Laboratories International, Inc. $CRL

King Luther Capital Management Corp lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 37.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,761 shares of the medical research company’s stock after buying an additional 17,781 shares during the quarter. King Luther Capital Management Corp’s holdings in Charles River Laboratories International were worth $12,919,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CRL. Jones Financial Companies Lllp increased its position in shares of Charles River Laboratories International by 167.6% during the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after buying an additional 1,074 shares during the period. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International during the first quarter worth $418,000. American Century Companies Inc. increased its position in shares of Charles River Laboratories International by 41.9% during the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after buying an additional 1,616 shares during the period. Brown Advisory Inc. increased its position in shares of Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after buying an additional 114 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Charles River Laboratories International by 3.9% during the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after buying an additional 3,198 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research reports. Wall Street Zen cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Robert W. Baird set a $213.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. Evercore restated an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. JPMorgan Chase & Co. reduced their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. Finally, Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $207.69.

Charles River Laboratories International Trading Up 5.0%

NYSE:CRL opened at $164.56 on Thursday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $7.93 billion, a price-to-earnings ratio of -43.77, a PEG ratio of 1.79 and a beta of 1.44. The firm has a fifty day simple moving average of $168.04 and a two-hundred day simple moving average of $181.10. Charles River Laboratories International, Inc. has a 12 month low of $132.58 and a 12 month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the company posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.